An observational study in Fetal Growth Restriction, sponsored by Assiut University. Recruiting at 1 site in Egypt. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Fetal Growth Retardation by Assiut University — 3 open to participants now, 3 under way, none of them phase 3. Fetal Growth Retardation · Assiut University.
Among the 10 studies in Fetal Growth Retardation by Assiut University, this one is one of 3 that started in 2026, is one of 6 observational ones, and was the 10th registered.
262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.
Browse Fetal Growth Retardation studies →3 of the 10 studies in Fetal Growth Retardation by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University
Ages 18+ · Women only · Healthy volunteers
Assiut University
Ages 18–45 · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 48 Fetal Growth Retardation studies recruiting now, 24 (50%) set no upper age limit and 21 (44%) stop at 75 or younger; 16 take children under 18; 24 take healthy volunteers.
This study: female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 28 is below the median of 200 across 145 observational studies indexed under Fetal Growth Retardation.
Median enrollment 84 across the 4 interventional studies, 130 across the 6 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,081 studies on the registry; 2,179 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Fetal Growth Retardation by Assiut University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluation of fetal cardiac functions in cases complicated with growth restriction
10% of pregnancies are, by the description, affected by the common obstetric issue known as intrauterine growth restriction (IUGR). IUGR is a significant contributor to prenatal mortality and morbidity. Cardiomyopathy is a reliable marker of the advancement of IUGR; in these babies, it begins during the early phases of fetal growth restriction and worsens as fetal impairment advances. IUGR is caused by placental dysfunction and this leads to a state of chronic hypoxia and metabolic stress and redistribution of blood flow towards vital organs, such as the brain, heart and adrenal glands. This hemodynamic compensation can itself contribute to a progressive deterioration of fetal cardiac function and myocardial remodeling. The myocardial performance index (MPI), also known as the Tei index, has emerged as a promising tool for the non-invasive evaluation of global fetal cardiac function, integrating both systolic and diastolic performance. To overcome some of the reproducibility-related limitations of the original technique, a modified version of the MPI (Mod-MPI) was introduced, which uses the opening and closing 'clicks' of the heart valves as more precise temporal landmarks. In recent years, numerous studies have investigated the role of MPI in the assessment of IUGR fetuses, and have suggested that this index may be altered early in gestation in response to chronic hypoxia and hemodynamic stress.
Fetuses with IUGR will be included in group 1. Fetuses with normal growth will be included in group 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Fetal weight less than 10th percentile
Procedure: Echocardiography
Fetal weight between 10th and 90th percentile
Procedure: Echocardiography
Modified MPI is obtained by placing the Doppler sample volume on the medial wall of the ascending aorta including the AV and MV, hence the movements of both valves are recorded simultaneously in the Doppler spectrum through measurements of the isovolumetric contraction time (ICT), isovolumetric relaxation time (IRT) and ejection time (ET). The isovolumetric contraction time (ICT) was measured from the closure of the MV to the opening of the AV, the ejection time (ET) from the opening to the closure of the AV, and the isovolumetric relaxation time (IRT) from the closure of the AV to the opening of the MV. The MPI (Tei index) was calculated using the following equation: MPI= (ICT + IRT)/ET
Measurement of MPI
Increased MPI means bad outcome
Time frame: 2 weeks
Start is estimated for Aug 2026; primary completion for Sep 2026, 1 month later.
Of 72 non-industry observational studies under Fetal Growth Retardation, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 170. This study's planned 1 month is below that.
Counting every sponsor, half of 73 studies reached it within 52 months; a quarter within 24 and three quarters within 170.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.